sales@ambeed.com

Structure Search

List Search MOL Search Structure Search

Hello, Sign in

Home Cart 0 Sign in

X

[ CAS No. 175278-17-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 175278-17-8

Chemical Structure| 175278-17-8

Chemical Structure| 175278-17-8

Structure of 175278-17-8 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 175278-17-8 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 175278-17-8 ]

SDS Specification

Alternatived Products of [ 175278-17-8 ]

Product Citations

Product Details of [ 175278-17-8 ]

CAS No. :	175278-17-8	MDL No. :	MFCD00203478
Formula :	C₇H₅BrF₃NO	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	ROSTYHNIIDIBEG-UHFFFAOYSA-N
M.W :	256.02	Pubchem ID :	688296
Synonyms :

Calculated chemistry of [ 175278-17-8 ] Expand+

Physicochemical Properties

Num. heavy atoms :	13
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.14
Num. rotatable bonds :	2
Num. H-bond acceptors :	4.0
Num. H-bond donors :	1.0
Molar Refractivity :	45.23
TPSA :	35.25 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.65 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.06
Log Po/w (XLOGP3) :	3.11
Log Po/w (WLOGP) :	4.2
Log Po/w (MLOGP) :	2.37
Log Po/w (SILICOS-IT) :	2.38
Consensus Log Po/w :	2.82

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.6
Solubility :	0.0649 mg/ml ; 0.000253 mol/l
Class :	Soluble
Log S (Ali) :	-3.52
Solubility :	0.0775 mg/ml ; 0.000303 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-3.52
Solubility :	0.077 mg/ml ; 0.000301 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	0.0
Synthetic accessibility :	1.62

Safety of [ 175278-17-8 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 175278-17-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 175278-17-8 ]
Downstream synthetic route of [ 175278-17-8 ]

[ 175278-17-8 ] Synthesis Path-Upstream 1~5

1
[ 461-82-5 ]
[ 175278-17-8 ]

Yield	Reaction Conditions	Operation in experiment
83%	With N-bromosuccinamide In acetonitrile at 0 - 20℃; for 4 h;	N-Bromosuccinamide (3.62 g, 20.34 mmol) was added to a solution of commercially available 4-(trifluoromethoxy)aniline (3.00 g, 1 6.95 mmol) in acetonitrile (30 mL) at 0°C. The resulting mixture was allowed to warm to roomtemperature and stirred for 4 hours. The solvent was removed under reduced pressure to give the crude product which was purified by column chromatography eluting in 10percent ethyl acetat/hexane to afford the title compound as brown oil (3.6 gm, 83percent): 1 H NMR (400 MHz, CDCI3) ö: 4.11 (bs, 2 H), 6.73 (d, 1 H), 6.99 (dd, 1 H), 7.31 (d, 1 H). LC-Ms (m/z): [M-H] = 253.1.
40%	Stage #1: With bromine In acetic acid at 20℃; for 2.16667 h; Stage #2: With sodium hydroxide In water; acetic acid	4-Trifluoromethoxyaniline (1.0 g, 5.6 mmol) was dissolved in glacial acetic acid (10 mL). Bromine (585 μL, 11 mmol) dissolved in glacial acetic acid (2 mL) was added with stirring during 10 minutes at room temperature. The resulting mixture was stirred at room temperature for 2 hours and then poured into water (100 mL). The solid formed (2,5-dibromo-4-trifluoromethoxyaniline) was filtered off. The filtrate was made alkaline with solid sodium hydroxide and extracted with dichloromethane (100 mL), dried (MgSO4) and concentrated (30°C; 200 mBar) to afford 0.57 g (40percent) of 2-bromo-4-trifluoromethoxyaniline.1H NMR (DMSO-d6): δ 5.55 (2H, bs), 6.85 (1H, d), 7.10 (1H, dd), 7.37 (1H, d).

Reference： [1] Patent: WO2015/100232, 2015, A2, . Location in patent: Page/Page column 102
[2] Journal of Medicinal Chemistry, 2007, vol. 50, # 1, p. 113 - 128
[3] Patent: EP1183229, 2005, B1, . Location in patent: Page/Page column 143-144
[4] Organic Letters, 2011, vol. 13, # 20, p. 5636 - 5639
[5] Journal of the American Chemical Society, 2016, vol. 138, # 40, p. 13147 - 13150
[6] Chinese Journal of Chemistry, 2018, vol. 36, # 9, p. 815 - 818

2
[ 88149-49-9 ]
[ 175278-17-8 ]

Reference： [1] Organic Letters, 2011, vol. 13, # 20, p. 5636 - 5639

3
[ 544-16-1 ]
[ 175278-17-8 ]
[ 468075-00-5 ]

Reference： [1] Patent: WO2004/31190, 2004, A1, . Location in patent: Page 39

4
[ 175278-17-8 ]
[ 468075-00-5 ]

Reference： [1] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 3, p. 282 - 286

5
[ 544-92-3 ]
[ 175278-17-8 ]
[ 549488-77-9 ]

Yield	Reaction Conditions	Operation in experiment
76%	at 163℃; for 6.5 h;	To a solution of 2-bromo-4-(trifluoromethoxy)aniline (15.1 g, 60.0 mmol) in N-methylpyrrolidone (100 mL) was added copper cyanide (10.6 g, 118 mmol) and the reaction mixture was stirred for 6.5 h at 163° C. After cooling to ambient temperature it was poured onto ice-water (300 mL) and aqueous ammonia (350 mL). The resulting brown precipitate was collected by filtration, washed with water (150 mL) and dissolved in dichloromethane (350 mL). The insoluble material was removed by filtration and the filtrate was washed with brine (100 mL) and dried over sodium sulfate. Purification by chromatography (SiO₂, heptane:ethyl acetate=95:5 to 25:75:) afforded the title compound (9.09 g, 76percent) as a brown solid. MS: m/e=405.1 [2M+H]⁺.

Reference： [1] Patent: US2006/79507, 2006, A1, . Location in patent: Page/Page column 16

[ 175278-17-8 ] Synthesis Path-Downstream 1~109

1
[ 175278-17-8 ]
[ 875143-35-4 ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 1066 - 1079

2
[ 79-04-9 ]
[ 175278-17-8 ]
<i>N</i>-(2-bromo-4-trifluoromethoxy-phenyl)-2-chloro-acetamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4444 - 4449

3
[ 24424-99-5 ]
[ 175278-17-8 ]
C₁₇H₂₁BrF₃NO₅ [ No CAS ]

Reference： [1]Synlett,2005,p. 3107 - 3108

4
[ 461-82-5 ]
[ 175278-17-8 ]

Yield	Reaction Conditions	Operation in experiment
95%	With bromine; In dichloromethane; water; for 3h;Reflux;	In a 250 mL four-necked flask equipped with a mechanical stirrer, a constant-pressure dropping funnel, a reflux condenser, and a thermometer, add 18 g of 4-trifluoromethoxyaniline,100 mL of dichloromethane and 100 mL of water, 400 mL of concentrated 4% bromine water was added dropwise with stirring at room temperature, and stirred at reflux for 3 h.Thin layer chromatography (TLC, dichloromethane: methanol volume ratio 3: 1) was followed to the end of the reaction. The organic phase after the reaction liquid was separated was concentrated to remove the organic solvent.The pink powdery solid product 4-trifluoromethoxy-2-bromoaniline was obtained with a yield of 95% and a purity of 97%.
83%	With N-bromosuccinamide; In acetonitrile; at 0 - 20℃; for 4h;	N-Bromosuccinamide (3.62 g, 20.34 mmol) was added to a solution of commercially available 4-(trifluoromethoxy)aniline (3.00 g, 1 6.95 mmol) in acetonitrile (30 mL) at 0C. The resulting mixture was allowed to warm to roomtemperature and stirred for 4 hours. The solvent was removed under reduced pressure to give the crude product which was purified by column chromatography eluting in 10% ethyl acetat/hexane to afford the title compound as brown oil (3.6 gm, 83%): 1 H NMR (400 MHz, CDCI3) oe: 4.11 (bs, 2 H), 6.73 (d, 1 H), 6.99 (dd, 1 H), 7.31 (d, 1 H). LC-Ms (m/z): [M-H] = 253.1.
40%		4-Trifluoromethoxyaniline (1.0 g, 5.6 mmol) was dissolved in glacial acetic acid (10 mL). Bromine (585 muL, 11 mmol) dissolved in glacial acetic acid (2 mL) was added with stirring during 10 minutes at room temperature. The resulting mixture was stirred at room temperature for 2 hours and then poured into water (100 mL). The solid formed (2,5-dibromo-4-trifluoromethoxyaniline) was filtered off. The filtrate was made alkaline with solid sodium hydroxide and extracted with dichloromethane (100 mL), dried (MgSO4) and concentrated (30C; 200 mBar) to afford 0.57 g (40%) of 2-bromo-4-trifluoromethoxyaniline.1H NMR (DMSO-d6): delta 5.55 (2H, bs), 6.85 (1H, d), 7.10 (1H, dd), 7.37 (1H, d).

Reference： [1]Patent: CN110590576,2019,A .Location in patent: Paragraph 0008
[2]Patent: WO2015/100232,2015,A2 .Location in patent: Page/Page column 102
[3]Journal of Medicinal Chemistry,2007,vol. 50,p. 113 - 128
[4]Patent: EP1183229,2005,B1 .Location in patent: Page/Page column 143-144
[5]Organic Letters,2011,vol. 13,p. 5636 - 5639
[6]Journal of the American Chemical Society,2016,vol. 138,p. 13147 - 13150
[7]Chinese Journal of Chemistry,2018,vol. 36,p. 815 - 818

5
[ 1885-14-9 ]
[ 175278-17-8 ]
(2-bromo-4-trifluoromethoxy-phenyl)-carbamic acid phenyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 113 - 128

6
[ 87120-72-7 ]
[ 175278-17-8 ]
[ 932700-84-0 ]

Yield	Reaction Conditions	Operation in experiment
		A solution of <strong>[175278-17-8]2-bromo-4-(trifluoromethyloxy)aniline</strong> (5.1 g), in 1 ,4-dioxane (30 ml.) was treated with bis(trichloromethyl) carbonate (2.2g). The mixture was heated to 1000C to give a clear solution then allowed to cool to ambient temperature. The solvent was evaporated and the residue was dissolved in dichloromethane (70ml) and 1 ,1- dimethylethyl 4-amino-1 -piperidinecarboxylate (4.0 g) was added. The mixture was stirred overnight at room temperature. Silica gel was added and the solvent was evaporated. The residue was loaded onto a silica gel chromatography column which was eluted with hexane/ethyl acetate 0-100% followed by chromatography on silica gel eluted with dichloromethane/methanol 0-10% to give the title compound as a white solid from diethyl ether (4.3 g).1HNMR delta (DMSO, 400 MHz): 1.25 (2H, m), 1.40 (9H, s), 1.79 (2H, m), 2.93 (2H, broad), 3.64 (1 H, m), 3.80 (2H, m), 7.21 (1 H, d), 7.35 (1 H, d), 7.66 (1 H, s), 7.91 (1 H, s), 8.19 (1 H, d).

Reference： [1]Patent: WO2007/107565,2007,A1 .Location in patent: Page/Page column 88

7
[ 5271-67-0 ]
[ 175278-17-8 ]
N-(2-bromo-4-(trifluoromethoxy)phenyl)thiophene-2-carboxamide [ No CAS ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 10425 - 10432

8
[ 175278-17-8 ]
[ 2243-83-6 ]
[ 955043-77-3 ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 10425 - 10432

9
[ 98-88-4 ]
[ 175278-17-8 ]
N-(2-bromo-4-(trifluoromethoxy)phenyl)benzamide [ No CAS ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 10425 - 10432

10
[ 175278-17-8 ]
2-phenyl-6-(trifluoromethoxy)benzo[d]oxazole [ No CAS ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 10425 - 10432

11
[ 175278-17-8 ]
2-(2-thienyl)-6-(trifluoromethoxy)benzo[d]oxazole [ No CAS ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 10425 - 10432

12
[ 175278-17-8 ]
3-{4-[3-(2-bromo-4-trifluoromethoxy-phenyl)-1-(4-<i>tert</i>-butyl-cyclohexyl)-ureidomethyl]-benzoylamino}-propionic acid methyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 113 - 128

13
[ 175278-17-8 ]
trans-3-{4-[3-(2-bromo-4-trifluoromethoxyphenyl)-1-(tert-butylcyclohexyl)ureidomethyl]benzoylamino}propionic acid [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 113 - 128

14
[ 175278-17-8 ]
2-<i>tert</i>-butoxycarbonylamino-5-trifluoromethoxy-benzoic acid <i>tert</i>-butyl ester [ No CAS ]

Reference： [1]Synlett,2005,p. 3107 - 3108

15
[ 175278-17-8 ]
<i>N</i>-(2-bromo-4-trifluoromethoxy-phenyl)-2-(5-methyl-4-<i>p</i>-tolyl-4<i>H</i>-[1,2,4]triazol-3-ylsulfanyl)-acetamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4444 - 4449

16
[ 175278-17-8 ]
2-([2-bromo-4-(trifluoromethoxy)phenyl]thio}methyl)-N-(cyanomethyl)cyclohexanecarboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 1066 - 1079

17
[ 175278-17-8 ]
C₁₇H₁₈⁽³⁾HF₃N₂O₄S [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 1066 - 1079

18
[ 175278-17-8 ]
2-([2-bromo-4-(trifluoromethoxy)phenyl]sulfonyl}methyl)-N-(cyanomethyl)cyclohexanecarboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 1066 - 1079

19
[ 175278-17-8 ]
4-(3-benzyl-2-oxo-5-trifluoromethoxy-2,3-dihydro-indol-1-ylmethyl)-benzamide [ No CAS ]

Reference： [1]Synlett,2004,p. 1049 - 1053

20
[ 175278-17-8 ]
[ 220953-28-6 ]

Reference： [1]Journal of Medicinal Chemistry,1999,vol. 42,p. 833 - 848

21
[ 175278-17-8 ]
[3-(2-bromo-4-trifluoromethoxy-phenyl)-5-methyl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl]-bis-(2-methoxy-ethyl)-amine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1999,vol. 42,p. 833 - 848

22
[ 175278-17-8 ]
[ 1027222-06-5 ]

Reference： [1]Journal of Medicinal Chemistry,1999,vol. 42,p. 833 - 848

23
[ 175278-17-8 ]
<i>N</i>-(2-bromo-4-trifluoromethoxy-phenyl)-<i>N</i>',<i>N</i>'-bis-(2-methoxy-ethyl)-2-methyl-5-nitro-pyrimidine-4,6-diamine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1999,vol. 42,p. 833 - 848

24
[ 374-35-6 ]
[ 175278-17-8 ]
N-(2-bromo-4-trifluoromethoxy-phenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide [ No CAS ]

Reference： [1]Patent: US6369273,2002,B1 .Location in patent: Page column 45

25
[ 75-44-5 ]
[ 27492-84-8 ]
[ 175278-17-8 ]
[ 617246-01-2 ]

Yield	Reaction Conditions	Operation in experiment
64%	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 0℃; for 2.25h;	To a cooled (0C) solution of phosgene (20% solution in toluene, 2.76 ml, 5.52 MMOL) in dry DICHLOROMETHANE (75 ml) was added, under an argon atmosphere, methyl 4-amino-2- methoxybenzoate (1 G, 5.52 MMOL) in one portion, followed by a dropwise addition of diisopropylethylamine (1.92 ML, 11.04 MMOL). The mixture was stirred for 15 minutes at 0C prior to the addition of 2-bromo-4 (trifluoromethoxy) aniline (0.83 ML, 5.52 MMOL). The reaction mixture was stirred at 0C for a further 2 hours and then was allowed to stir at room temperature overnight. The organic phase was washed with 1 N aq. HCI (2x), sat. aq. NAHCO3, dried over MGS04 and concentrated in vacuo to give a solid residue which was recrystallized in hot acetonitrile. The fine crystalline solid was filtered off, washed with cold acetonitrile and dried in vacuo to give the title compound Ex 106 as a pale-orange solid (1. 64G, 3.54 mmol, 64%). 'H-NMR (DMSO-d6) : 6 3.74 (s, 3H), 3.80 (s, 3H), 7.02 (d, 1H), 7.38 (s, 1H), 7.42 (d, 1H), 7.69 (d, 1H), 7.74 (s, 1H), 8.17 (d, 1H), 8.36 (s, 1H), 9.85 (s, 1H)

Reference： [1]Patent: WO2004/48319,2004,A1 .Location in patent: Page 66

26
[ 544-16-1 ]
[ 175278-17-8 ]
[ 468075-00-5 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogenchloride; copper(II) chloride; In acetonitrile; at 20℃; for 1h;	To anhydrous copper [(II)] chloride (6.3g, 47mmol) in acetonitrile (lOOmL) was added tert-butyl nitrite (6.85mL, [58MMOL),] followed dropwise by a solution of [2-BROMO-4- (TRIFLUOROMETHOXY)] aniline (lOg, 39mmol) in acetonitrile [(15ML).] The solution was stirred at ambient temperature for 1 hour then poured into hydrochloric acid (250mL, 2M). The suspension formed was extracted with diethyl ether [(2X250ML)] and the extracts were dried [(MGS04).] Concentration yielded the title compound as an oil (7.82g, [28MMOL).] [ON] (360 MHz, [CDCL3)] : 7.51 [(1H,] d, J 3.2Hz), 7.48 [(1H,] d, J 8.8Hz), 7.15 [(1H,] dd, J 3.2 and 8.8Hz).

Reference： [1]Patent: WO2004/31190,2004,A1 .Location in patent: Page 39

27
[ 544-92-3 ]
[ 175278-17-8 ]
[ 549488-77-9 ]

Yield	Reaction Conditions	Operation in experiment
76%	In 1-methyl-pyrrolidin-2-one; at 163℃; for 6.5h;	To a solution of <strong>[175278-17-8]2-bromo-4-(trifluoromethoxy)aniline</strong> (15.1 g, 60.0 mmol) in N-methylpyrrolidone (100 mL) was added copper cyanide (10.6 g, 118 mmol) and the reaction mixture was stirred for 6.5 h at 163 C. After cooling to ambient temperature it was poured onto ice-water (300 mL) and aqueous ammonia (350 mL). The resulting brown precipitate was collected by filtration, washed with water (150 mL) and dissolved in dichloromethane (350 mL). The insoluble material was removed by filtration and the filtrate was washed with brine (100 mL) and dried over sodium sulfate. Purification by chromatography (SiO2, heptane:ethyl acetate=95:5 to 25:75:) afforded the title compound (9.09 g, 76%) as a brown solid. MS: m/e=405.1 [2M+H]+.

Reference： [1]Patent: US2006/79507,2006,A1 .Location in patent: Page/Page column 16

28
C₁₀H₁₀ClNO₄ [ No CAS ]
[ 175278-17-8 ]
[ 617246-01-2 ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane; toluene; at 0 - 20℃;	Example 169 4- [3- (2-Bromo-4-trifluoromethoxy-phenyl)-ureido]-2-methoxy-benzoic acid methyl ester To a cooled (0C) solution of phosgene (20% solution in toluene, 2.76 ml, 5.52 mmol) in dry dichloromethane (75 ml) was added, under an argon atmosphere, methyl 4-amino-2- methoxybenzoate (1g, 5.52 mmol) in one portion, followed by a dropwise addition of diisopropylethylamine (1.92 ml, 11.04 mmol). The mixture was stirred for 15 minutes at 0C prior to the addition of 2-bromo-4 (trifluoromethoxy) aniline (0. 83 ml, 5.52 mmol). The reaction mixture was stirred at 0C for a further 2 hours and then was allowed to stir at room temperature overnight. The organic phase was washed with 1 N aq. HCI (2x), sat. aq. NaHCO3, dried over MgS04 and concentrated in vacuo to give a solid residue which was recrystallized in hot acetonitrile. The fine crystalline solid was filtered off, washed with cold acetonitrile and dried in vacuo to give the title compound Ex 169 as a pale-orange solid (1.64g, 3.54 mmol, 64%). 'H-NMR (DMSO-d6) : J 3.74 (s, 3H), 3.80 (s, 3H), 7.02 (d, 1H), 7.38 (s, 1H), 7.42 (d, 1H), 7.69 (d, 1H), 7.74 (s, 1H), 8.17 (d, 1H), 8. 36 (s, 1H), 9.85 (s, 1H)

Reference： [1]Patent: WO2003/87045,2003,A1 .Location in patent: Page/Page column 105

Yield	Reaction Conditions	Operation in experiment
0.57 g (40%)		3-{4-[3-(2-Bromo-4-trifluoromethoxyphenyl)-1-(trans-4-tert-butylcyclohexyl)ureidomethyl]benzoylamino}propionic Acid 4-Trifluoromethoxyaniline (1.0 g, 5.6 mmol) was dissolved in glacial acetic acid (10 mL). Bromine (585 muL, 11 mmol) dissolved in glacial acetic acid (2 mL) was added with stirring during 10 minutes at room temperature. The resulting mixture was stirred at room temperature for 2 hours and then poured into water (100 mL). The solid formed (2,5-dibromo-4-trifluoromethoxyaniline) was filtered off. The filtrate was made alkaline with solid sodium hydroxide and extracted with dichloromethane (100 mL), dried (MgSO4) and concentrated (30 C.; 200 mBar) to afford 0.57 g (40%) of 2-bromo-4-trifluoromethoxyaniline. 1H NMR (DMSO-d6): delta5.55 (2H, bs), 6.85 (1H, d), 7.10 (1H, dd), 7.37 (1H, d).

30
[ 175278-17-8 ]
[ 231296-94-9 ]

Yield	Reaction Conditions	Operation in experiment
		Step 1. Methyl trans-2-Amino-5-(trifluoromethoxy)cinnamate The title compound was prepared according to the procedure described in step 1 of Example 133 from <strong>[175278-17-8]2-bromo-4-(trifluoromethoxy)aniline</strong>. 1H-NMR (CDCl3) delta: 7.74 (1H, d, 15.8 Hz), 7.23-7.02 (2H, m), 6.68 (1H, d, 8.72 Hz), 6.36 (1H, d, 15.8 Hz), 4.00 (2H, br s), 3.81 (3H, s).

Reference： [1]Patent: US6608070,2003,B1

31
[ 32315-10-9 ]
[ 175278-17-8 ]
C₉H₄BrCl₃F₃NO₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In 1,4-dioxane; at 100℃;	A solution of <strong>[175278-17-8]2-bromo-4-(trifluoromethyloxy)aniline</strong> (5.1 g), in 1,4-dioxane (30 ml_) was treated with bis(trichloromethyl) carbonate (2.2g). The mixture was heated to 100 0C to give a clear solution then allowed to cool to ambient temperature. The solvent was evaporated and the residue was dissolved in dichloromethane (70 mL) and 1 ,1- dimethylethyl 4-amino-1 -piperidinecarboxylate (4.0 g) was added. The mixture was stirred overnight at room temperature. Silica gel was added and the solvent was evaporated. The residue was loaded onto a silica gel chromatography column which was eluted with hexane/ethyl acetate 0-100% followed by chromatography on silica gel eluted with dichloromethane/methanol 0-10% to give the title compound as a white solid from diethyl ether (4.3 g).1HNMR D(DMSO, 400 MHz) 1.25 (2H, m), 1.40 (9H, s), 1.79 (2H, m), 2.93 (2H, broad), 3.64 (1 H, m), 3.80 (2H, m), 7.21 (1H, d), 7.35 (1H, d), 7.66 (1H, s), 7.91 (1 H, s), 8.19 (1 H, d).

Reference： [1]Patent: WO2007/36711,2007,A1 .Location in patent: Page/Page column 55

32
[ 175278-17-8 ]
[ 766-97-2 ]
[ 900183-39-3 ]

Yield	Reaction Conditions	Operation in experiment
		Reference example 53 [1-Allyl-5-(trifluoromethoxy-)-1H-indazol-3-yl](4-methylphenyl)methanone The subject compound was prepared in the same method as Reference example 46 and then Reference example 49 by using <strong>[175278-17-8]4-(trifluoromethoxy)-2-bromoaniline</strong> and 4-ethynyltoluene. 1H NMR (CDCl3, 400 MHz) delta 8.36 (s, 1 H), 8.26 (d, 2 H, J = 8.2 Hz), 7.49 (d, 1 H, J = 9.0 Hz), 7.34 (d, 1 H, J = 9.0 Hz), 7.33 (d, 2 H, J = 8.2 Hz), 6.07 (ddt, 1 H, J = 10.2, 17.2, 5.5 Hz), 5.33 (d, 1 H, J = 10.2 Hz), 5.23 (d, 1 H, J = 17.2 Hz), 5.15 (d, 2 H, J = 5.5 Hz).

Reference： [1]Patent: EP1837329,2007,A1

33
[ 175278-17-8 ]
2-[(phenylsulfonyl)amino]-4-(trifluoromethoxy)benzoic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 94 2-[(phenylsulfonyl)amino]-4-(trifluoromethoxy)benzoic acid The desired product was prepared by substituting <strong>[175278-17-8]2-bromo-4-(trifluoromethoxy)aniline</strong> for 2-bromo-4-isopropylaniline in Examples 2A-D. MS (ESI(+)) m/e 362 (M+H)+, 379 (M+NH4)+, 384 (M+Na)+; (ESI(-)) m/e 360 (M-H)-; 1H NMR (300 MHz, DMSO-d6) delta 7.76 (m, 1H), 7.73 (m, 1H), 7.68 (m, 1H), 7.51 (m, 3H), 7.39 (d, 1H), 7.20 (m, 1H).

Reference： [1]Patent: US2004/157836,2004,A1

34
[ 75-36-5 ]
[ 175278-17-8 ]
[ 131395-29-4 ]

Reference： [1]Angewandte Chemie - International Edition,2007,vol. 46,p. 7509 - 7512

35
[ 292638-85-8 ]
[ 175278-17-8 ]
[ 231296-94-9 ]

Yield	Reaction Conditions	Operation in experiment
	With palladium diacetate; triethylamine; tris-(o-tolyl)phosphine; In acetonitrile; for 4h;Inert atmosphere; Reflux;	A mixture of <strong>[175278-17-8]2-bromo-4-(trifluoromethoxy)aniline</strong> 17 (Maybridge, 2.048 g, 8.00 mmol), methyl acrylate (1.80 mL, 20.0 mmol), Pd(OAc)2 (215.5 mg, 0.960 mmol), tri-o-tolylphosphine (1.169 g, 3.84 mmol), and dry Et3N (4.30 mL, 30.9 mmol) in dry CH3CN (16.0 mL) was stirred under reflux conditions under N2 for 4 h, then concentrated in vacuo. The residue was partitioned between H2O (30 mL) and AcOEt (30 mL). The organic layer was separated and the aqueous layer was extracted with AcOEt (30 mL × 2). The organic layers were combined, dried over anhydrous MgSO4, filtered, and concentrated in vacuo to afford 3.630 g of the title product 21 (crude). This compound was used for the next step without further purification. 1H NMR (270 MHz, CDCl3) delta 7.74 (1H, d, J = 15.8 Hz), 7.23-7.02 (2H, m), 6.68 (1H, d, J = 8.72 Hz), 6.36 (1H, d, J = 15.8 Hz), 4.00 (2H, br s), 3.81 (3H, s).

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 629 - 633
[2]European Journal of Medicinal Chemistry,2012,vol. 50,p. 179 - 195

36
[ 175278-17-8 ]
[ 883546-30-3 ]

Reference： [1]Angewandte Chemie - International Edition,2008,vol. 47,p. 888 - 890

37
[ 175278-17-8 ]
[ 825633-93-0 ]
[ 1041014-98-5 ]

Reference： [1]Tetrahedron,2008,vol. 64,p. 6030 - 6037

38
[ 175278-17-8 ]
[ 393860-82-7 ]
3-[2-bromo-4-(trifluoromethoxy)anilino]-5-chloro-1-(4-methoxybenzyl)-2(1H)-pyrazinone [ No CAS ]

Reference： [1]Tetrahedron,2008,vol. 64,p. 8128 - 8133

39
[ 407-25-0 ]
[ 175278-17-8 ]
[ 1068977-35-4 ]

Yield	Reaction Conditions	Operation in experiment
	With pyridine; In dichloromethane; at 20℃;	Example 177; 2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethoxy- indol- 1 -vD-amide; Step 1 : A solution of <strong>[175278-17-8]2-bromo-4-trifluoromethoxy-phenylamine</strong> (7.6 g, 29.7 mmol) in DCM (60 niL) is treated with TFAA (5 rnL, 35.6 mmol) and pyridine (2.87 mL, 35.6 mmol), and stirred at rt overnight. The mixture is diluted with H2O (150 mL), and extracted with DCM (3 x 150 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is diluted with MeCN (60 mL), treated with trans-cxotyl bromide (4.6 mL, 44.5 mmol) and K2CO3 (8.1 g, 59 mmol), heated at reflux for 1 h, and then stirred at rt for 2 h. The mixture is filtered through a pad of Celite and the filtrate is concentrated. The residue is purified by silica gel chromatography eluting with 0% - 15% EtOAc in heptane to afford N-(2- bromo-4-trifluoromethoxy-phenyl)-lambda/-but-2-enyl-2,2,2-trifluoro-acetamide (10.5 g, 87%). MS: 406 (M+); 1H NMR (300 MHz, CDCl3): delta 7.56 (s, IH), 7.22 (m, 2H), 5.52 (m, 2H), 4.86 (m, IH), 3.57 (m, IH), 1.65 (d, 3H).

Reference： [1]Patent: WO2008/121670,2008,A1 .Location in patent: Page/Page column 173

40
[ 6783-05-7 ]
[ 175278-17-8 ]
[ 1054567-50-8 ]

Reference： [1]Angewandte Chemie - International Edition,2008,vol. 47,p. 5056 - 5059

41
[ 175278-17-8 ]
trans-2-[4-(trifluoromethyl)phenyl]vinylboronic acid [ No CAS ]
[ 1054568-04-5 ]

Reference： [1]Angewandte Chemie - International Edition,2008,vol. 47,p. 5056 - 5059

42
[ 1173983-06-6 ]
[ 175278-17-8 ]
[ 1173983-28-2 ]

Yield	Reaction Conditions	Operation in experiment
29%		Reference Example 58 Ethyl 4-[2-[2-bromo-4-(trifluoromethoxy)phenyl]amino}-4-chloro-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]butanoate A mixture of ethyl 4-[2,4-dichloro-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]butanoate (Reference Example 33; 3.00 g, 8.08 mmol), <strong>[175278-17-8]2-bromo-4-(trifluoromethoxy)aniline</strong> (2.44 mL, 16.16 mmol), p-toluenesulfonic acid monohydrate (1.64 g, 8.65 mmol) and xylene (7.0 mL) was stirred at 130 C. for 12 hr. After cooling, the reaction mixture was neutralized with aqueous saturated sodium hydrogen carbonate and extracted with ethyl acetate (*3). The combined organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography eluding with a 0-15% ethyl acetate/n-hexane gradient mixture to give the title compound as a pale red oil (1.38 g, 2.34 mmol, 29%). 1H NMR (CDCl3) delta: 0.87 (t, J=7.5 Hz, 6H), 1.23 (t, J=7.2 Hz, 3H), 1.66-1.86 (m, 4H), 2.10-2.18 (m, 2H), 2.46 (t, J=6.3 Hz, 2H), 3.00-3.04 (m, 1H), 4.13 (q, J=7.2 Hz, 2H), 4.30 (t, J=8.1 Hz, 2H), 6.93 (d, J=8.1 Hz, 1H), 7.06 (s, 1H), 7.14-7.31 (m, 1H), 7.45 (s, 1H), 7.61-7.70 (m, 1H), 8.47-8.50 (m, 1H). MS Calcd.: 589, MS Found: 590 (M+H).

Reference： [1]Patent: US2009/186879,2009,A1 .Location in patent: Page/Page column 61

43
[ 24850-33-7 ]
[ 175278-17-8 ]
2-allyl-4-(trifluoromethoxy)aniline [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With tetrakis(triphenylphosphine) palladium(0); In N,N-dimethyl-formamide; at 80℃; for 16h;	To a solution of <strong>[175278-17-8]2-bromo-4-(trifluoromethoxy)aniline</strong> (75 g, 293 mmol) in DMF (1000 ml) was added Pd(PPh3)4 (13.5 g, 11.7 mmol) and allyltributyltin (116 g, 351 mmol) and the reaction mixture was stirred at 80 C. for 16 h. The mixture was cooled to room temperature and saturated aqueous KF solution was added. The mixture was diluted with ethyl acetate (1500 mL) and washed with 1:1 H2O: saturated aqueous NaCl solution (2×750 mL) and saturated aqueous KF (1×). The aqueous layers were combined and extracted with ethyl acetate (250 mL). The organic extracts were combined, dried over MgSO4, filtered and concentrated under reduced pressure to give the crude product, which was absorbed onto silica and purified by chromatography eluting with 1% ethyl acetate in petroleum ether to give the title compound. (0563) LC-MS: Rt 1.00 mins; MS m/z 218.0 [M+H]+; Method H (0564) 1H NMR (400 MHz, MeOD) delta 3.27 (2H, dd), 5.07-5.14 (2H, m), 5.92-5.99 (1H, m), 6.72 (1H, dd), 6.88-6.89 (2H, m).

Reference： [1]Tetrahedron Letters,2009,vol. 50,p. 1911 - 1913
[2]Patent: US2015/329549,2015,A1 .Location in patent: Paragraph 0562-0564

44
10-methyl-4-oxa-tricyclo-[5.2.1.0(2,6)]-dec-8-en-10-ol [ No CAS ]
[ 175278-17-8 ]
C₁₇H₁₆F₃NO₂ [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2010,vol. 49,p. 4455 - 4458

45
[ 1493-27-2 ]
[ 175278-17-8 ]
[ 1207887-01-1 ]

Reference： [1]Journal of Combinatorial Chemistry,2010,vol. 12,p. 222 - 224

46
[ 140-88-5 ]
[ 175278-17-8 ]
[ 1239463-16-1 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; tris-(o-tolyl)phosphine;palladium diacetate; In N,N-dimethyl-formamide; at 120℃; for 18h;Inert atmosphere;	To a mixture of <strong>[175278-17-8]2-bromo-4-(trifluoromethoxy)aniline</strong> (1.00 mmol), triethylamine (1.5 mmol) and P(o-tol)3 (0.40 mmol) in DMF (0.5 M) in a glass pressure tube under nitrogen gas were added ethyl acrylate (1.0 mmol) and palladium acetate (0.20 mmol). The tube was sealed and heated to 120 0C for 18 h. The resulting solution was concentrated under vacuum and purified by column chromatography. Retention time (min) = 2.467, method [1], MS(ESI) 276.1 (M+H).

Reference： [1]Patent: WO2010/91310,2010,A1 .Location in patent: Page/Page column 170

47
C₁₃H₂₁NO₆ [ No CAS ]
[ 175278-17-8 ]
[ 1240382-13-1 ]

Reference： [1]Organic Letters,2010,vol. 12,p. 3574 - 3577

48
[ 175278-17-8 ]
[ 752132-49-3 ]

Reference： [1]Organic and Biomolecular Chemistry,2010,vol. 8,p. 5324 - 5332

49
[ 536-74-3 ]
[ 175278-17-8 ]
[ 1181455-52-6 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine;bis-triphenylphosphine-palladium(II) chloride; copper(l) iodide; In tetrahydrofuran; at 20 - 80℃;	To a mixture of <strong>[175278-17-8]2-bromo-4-trifluoromethoxyaniline</strong> (0.500 g), cupper iodide (I) (18.6 mg), bis(triphenylphosphine)palladium (II) dichloride (68.5 mg), triethylamine (0.817 mL) and tetrahydrofuran (7.8 mL) was added phenylacetylene (0.279 mL) at room temperature under stirring, and the mixture was stirred at 80 C. for 16 hours. The reaction mixture was cooled to room temperature, diluted with diethyl ether (30 mL) and then filtered through celite (registered trademark). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluting solvent: ethyl acetate-hexane) to obtain the title compound (206 mg).1H-NMR (CDCl3) delta ppm:4.32 (2H, br s), 6.70 (1H, d, J=8.8 Hz), 6.95-7.10 (1H, m), 7.20-7.30 (1H, m), 7.30-7.45 (3H, m), 7.45-7.60 (2H, m).

Reference： [1]Organic Letters,2009,vol. 11,p. 3598 - 3601
[2]Patent: US2012/129890,2012,A1 .Location in patent: Page/Page column 15
[3]Advanced Synthesis and Catalysis,2018,vol. 360,p. 4054 - 4059

50
[ 25015-63-8 ]
[ 175278-17-8 ]
[ 1058062-64-8 ]

Reference： [1]Organic Letters,2009,vol. 11,p. 3598 - 3601

51
[ 108-24-7 ]
[ 175278-17-8 ]
[ 131395-29-4 ]

Reference： [1]Synlett,2011,p. 241 - 244

52
[ 175278-17-8 ]
[ 1296885-52-3 ]

Reference： [1]Synlett,2011,p. 241 - 244

53
[ 175278-17-8 ]
[ 1296885-56-7 ]

Reference： [1]Synlett,2011,p. 241 - 244
[2]Synlett,2011,p. 241 - 244
[3]Synlett,2011,p. 241 - 244

54
[ 175278-17-8 ]
[ 1296885-58-9 ]

Reference： [1]Synlett,2011,p. 241 - 244

55
[ 75-15-0 ]
[ 175278-17-8 ]
[ 235101-85-6 ]

Reference： [1]Organic Letters,2011,vol. 13,p. 3202 - 3205

56
[ 108-86-1 ]
[ 201230-82-2 ]
[ 175278-17-8 ]
[ 1352730-78-9 ]

Reference： [1]Chemistry - A European Journal,2011,vol. 17,p. 12246 - 12249

57
[ 88149-49-9 ]
[ 175278-17-8 ]

Reference： [1]Organic Letters,2011,vol. 13,p. 5636 - 5639

58
[ 175278-17-8 ]
[ 388116-27-6 ]
[ 1335243-01-0 ]

Reference： [1]Organic Letters,2011,vol. 13,p. 5636 - 5639

59
[ 175278-17-8 ]
[ 388116-27-6 ]
[ 1335242-71-1 ]

Reference： [1]Organic Letters,2011,vol. 13,p. 5636 - 5639

60
[ 5427-82-7 ]
[ 175278-17-8 ]
[ 1355042-60-2 ]

Reference： [1]Journal of Organic Chemistry,2012,vol. 77,p. 1507 - 1519

61
[ 58881-45-1 ]
[ 175278-17-8 ]
[ 1355042-62-4 ]

Reference： [1]Journal of Organic Chemistry,2012,vol. 77,p. 1507 - 1519

62
[ 175278-17-8 ]
[ 231296-95-0 ]

Reference： [1]European Journal of Medicinal Chemistry,2012,vol. 50,p. 179 - 195

63
[ 175278-17-8 ]
methyl {2-[(4-methylpyridin-2-yl)carbonyl]-5-(trifluoromethoxy)-1H-indol-3-yl}acetate [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2012,vol. 50,p. 179 - 195

64
[ 175278-17-8 ]
[ 231293-45-1 ]

Reference： [1]European Journal of Medicinal Chemistry,2012,vol. 50,p. 179 - 195

65
[ 175278-17-8 ]
methyl {2-[(4-ethylpyridin-2-yl)carbonyl]-5-(trifluoromethoxy)-1H-indol-3-yl}acetate [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2012,vol. 50,p. 179 - 195

66
[ 175278-17-8 ]
{2-[(4-ethylpyridin-2-yl)carbonyl]-5-(trifluoromethoxy)-1H-indol-3-yl}acetic acid [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2012,vol. 50,p. 179 - 195

67
[ 1692-15-5 ]
[ 175278-17-8 ]
[ 1214387-77-5 ]

Reference： [1]Angewandte Chemie - International Edition,2012,vol. 51,p. 5920 - 5923

68
[ 109-92-2 ]
[ 175278-17-8 ]
[ 1391575-77-1 ]

Reference： [1]Journal of the American Chemical Society,2012,vol. 134,p. 12466 - 12469
[2]Journal of the American Chemical Society,2012,vol. 134,p. 18147 - 18147,1

69
[ 192182-54-0 ]
[ 175278-17-8 ]
[ 1412911-98-8 ]

Reference： [1]Tetrahedron Letters,2012,vol. 53,p. 6280 - 6287,8

70
[ 192182-54-0 ]
[ 175278-17-8 ]
[ 1412912-60-7 ]

Reference： [1]Tetrahedron Letters,2012,vol. 53,p. 6280 - 6287,8

71
[ 175278-17-8 ]
[ 1426812-89-6 ]

Reference： [1]Advanced synthesis and catalysis,2012,vol. 354,p. 2473 - 2483,11
[2]Organic Letters,2013,vol. 15,p. 1468 - 1471

72
[ 175278-17-8 ]
N-(5-(trifluoromethoxy)biphenyl-2-yl)benzenesulfonamide [ No CAS ]

Reference： [1]Advanced synthesis and catalysis,2012,vol. 354,p. 2473 - 2483,11

73
[ 175278-17-8 ]
4-methyl-N-(2-(naphthalen-2-yl)-4-(trifluoromethoxy)phenyl)benzenesulfonamide [ No CAS ]

Reference： [1]Advanced synthesis and catalysis,2012,vol. 354,p. 2473 - 2483,11

74
[ 175278-17-8 ]
C₂₃H₁₆F₃NO₃S [ No CAS ]

Reference： [1]Advanced synthesis and catalysis,2012,vol. 354,p. 2473 - 2483,11

75
[ 175278-17-8 ]
[ 98-80-6 ]
[ 131395-27-2 ]

Reference： [1]Advanced synthesis and catalysis,2012,vol. 354,p. 2473 - 2483,11
[2]Organic Letters,2013,vol. 15,p. 1468 - 1471
[3]Organic Letters,2017,vol. 19,p. 4134 - 4137
[4]Journal of Organic Chemistry,2018,vol. 83,p. 3840 - 3856

76
[ 17933-03-8 ]
[ 175278-17-8 ]
N-(3'-methyl-5-(trifluoromethoxy)biphenyl-2-yl)benzenesulfonamide [ No CAS ]

Reference： [1]Advanced synthesis and catalysis,2012,vol. 354,p. 2473 - 2483,11

77
[ 17933-03-8 ]
[ 175278-17-8 ]
3'-methyl-5-(trifluoromethoxy)biphenyl-2-amine [ No CAS ]

Reference： [1]Advanced synthesis and catalysis,2012,vol. 354,p. 2473 - 2483,11
[2]Organic Letters,2017,vol. 19,p. 4134 - 4137
[3]Organic Letters,2019,vol. 21,p. 1182 - 1186

78
[ 13922-41-3 ]
[ 175278-17-8 ]
4-methyl-N-(2-(naphthalen-1-yl)-4-(trifluoromethoxy)phenyl)benzenesulfonamide [ No CAS ]

Reference： [1]Advanced synthesis and catalysis,2012,vol. 354,p. 2473 - 2483,11

79
[ 13922-41-3 ]
[ 175278-17-8 ]
2-(naphthalen-1-yl)-4-(trifluoromethoxy)aniline [ No CAS ]

Reference： [1]Chemical Communications,2017,vol. 53,p. 6247 - 6250
[2]Advanced synthesis and catalysis,2012,vol. 354,p. 2473 - 2483,11
[3]Advanced Synthesis and Catalysis,2019,vol. 361,p. 683 - 689

80
[ 32316-92-0 ]
[ 175278-17-8 ]
2-(naphthalen-2-yl)-4-(trifluoromethoxy)aniline [ No CAS ]

Reference： [1]Advanced synthesis and catalysis,2012,vol. 354,p. 2473 - 2483,11

81
[ 110-52-1 ]
[ 175278-17-8 ]
C₁₁H₁₁BrF₃NO [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2012,vol. 51,p. 12307 - 12310
Angew. Chem.,2012,vol. 124,p. 12307 - 12310,4

82
[ 175278-17-8 ]
[ 1438277-65-6 ]

Reference： [1]Angewandte Chemie - International Edition,2012,vol. 51,p. 12307 - 12310
Angew. Chem.,2012,vol. 124,p. 12307 - 12310,4

83
[ 175278-17-8 ]
[ 1438277-51-0 ]

Reference： [1]Angewandte Chemie - International Edition,2012,vol. 51,p. 12307 - 12310
Angew. Chem.,2012,vol. 124,p. 12307 - 12310,4

84
[ 175278-17-8 ]
[ 1443006-21-0 ]

Reference： [1]Angewandte Chemie - International Edition,2012,vol. 51,p. 12307 - 12310
Angew. Chem.,2012,vol. 124,p. 12307 - 12310,4

85
[ 4023-34-1 ]
[ 175278-17-8 ]
C₁₁H₉BrF₃NO₂ [ No CAS ]

Reference： [1]Organic Letters,2013,vol. 15,p. 1354 - 1357

86
[ 175278-17-8 ]
[ 1426813-11-7 ]

Reference： [1]Organic Letters,2013,vol. 15,p. 1468 - 1471

87
[ 103-71-9 ]
[ 175278-17-8 ]
[ 13939-06-5 ]
[ 1448440-21-8 ]

Reference： [1]Chemistry - A European Journal,2013,vol. 19,p. 6230 - 6233

88
[ 552-89-6 ]
[ 175278-17-8 ]
[ 1453279-86-1 ]

Reference： [1]Synlett,2013,vol. 24,p. 1573 - 1577

89
[ 552-89-6 ]
[ 175278-17-8 ]
[ 1453279-93-0 ]

Reference： [1]Synlett,2013,vol. 24,p. 1573 - 1577

90
[ 201230-82-2 ]
[ 62-53-3 ]
[ 175278-17-8 ]
[ 149-73-5 ]
[ 1593583-20-0 ]

Reference： [1]Angewandte Chemie - International Edition,2014,vol. 53,p. 1420 - 1424
Angew. Chem.,2014,vol. 126,p. 1444 - 1448,5

91
[ 25015-63-8 ]
[ 175278-17-8 ]
[ 1451391-22-2 ]

Reference： [1]Journal of the American Chemical Society,2020
[2]Journal of Organic Chemistry,2014,vol. 79,p. 2781 - 2791
[3]Organic Letters,2015,vol. 17,p. 802 - 805
[4]Journal of the American Chemical Society,2016,vol. 138,p. 13271 - 13280

92
[ 175278-17-8 ]
[ 1579291-78-3 ]

Reference： [1]Journal of Organic Chemistry,2014,vol. 79,p. 2781 - 2791
[2]Organic Letters,2015,vol. 17,p. 802 - 805

93
[ 175278-17-8 ]
[ 1579291-55-6 ]

Reference： [1]Journal of Organic Chemistry,2014,vol. 79,p. 2781 - 2791

94
[ 175278-17-8 ]
[ 1579291-65-8 ]

Reference： [1]Journal of Organic Chemistry,2014,vol. 79,p. 2781 - 2791

95
N'-((2'-bromo-[1,1’-biphenyl]-2-yl)methylene)-4-methylbenzenesulfonohydrazide [ No CAS ]
[ 175278-17-8 ]
N-(2-bromo-4-(trifluoromethoxy)phenyl)-9H-fluoren-9-amine [ No CAS ]

Reference： [1]ACS Catalysis,2014,vol. 4,p. 4498 - 4503

96
[ 175278-17-8 ]
C₈H₆ClF₃N₂O₂ [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 282 - 286

97
[ 175278-17-8 ]
[ 468075-00-5 ]

Yield	Reaction Conditions	Operation in experiment
	With tert.-butylnitrite; copper dichloride; In acetonitrile; at 70℃; for 3h;	General procedure: A mixture of isoamyl nitrite (4 mL, 30 mmol), copper (II) chloride (3.22 g, 24 mmol) and 4-bromo-2-(trifluoromethoxy)aniline (Compound 30A) (5.1 g, 20 mmol) in acetonitrile (80 mL) was heated at 70 C for 3 hours. The mixture was poured into an aqueous HC1 solution (0.5 M, 50 mL) and extracted with ethyl acetate (50 mL x 2). The combined extracts were washed with water (50 mL x 4) and brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified with flash column chromatography on silica gel (petroleum ether) to afford Compound 30B. LC-MS (ESI) m/z: non-ionizable compound under routine conditions used. ?H-NIVIR (DMSO-d6, 400 IVII{z): 5 (ppm) 7.33-7.3 5 (m, 1H), 7.37-7.40 (m, 1H), 7.48 (t, J= 1.6 Hz, 1H).

Reference： [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 282 - 286
[2]Patent: WO2019/133770,2019,A2 .Location in patent: Paragraph 00624; 00625; 00626; 001944; 001945; 001946

98
[ 175278-17-8 ]
[ 1261649-12-0 ]

Reference： [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 282 - 286

99
[ 175278-17-8 ]
1-(2-chloro-5-(trifluoromethoxy)phenyl)-4-methylpyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazine [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 282 - 286

100
[ 175278-17-8 ]
methyl-2-(2-azido-5-trifluoromethoxyphenyl)cyclohex-1-enecarboxylate [ No CAS ]

Reference： [1]Organic Letters,2015,vol. 17,p. 802 - 805

101
[ 175278-17-8 ]
methyl-6-trifluoromethoxy-2,3,4,4a-tetrahydro-1H-carbazole-4a-carboxylate [ No CAS ]

Reference： [1]Organic Letters,2015,vol. 17,p. 802 - 805

102
[ 175278-17-8 ]
2-({4-(trifluoromethoxy)-2-[(trimethylsilyl)ethynyl]phenyl}amino)ethan-1-ol [ No CAS ]

Reference： [1]Organic Letters,2015,vol. 17,p. 1774 - 1777

103
[ 175278-17-8 ]
2-[2-ethynyl-4-(trifluoromethoxy)phenyl]amino}ethan-1-ol [ No CAS ]

Reference： [1]Organic Letters,2015,vol. 17,p. 1774 - 1777

104
[ 175278-17-8 ]
2-[2-(phenylbuta-1,3-diyn-1-yl)-4-(trifluoromethoxy)phenyl]amino}ethan-1-ol [ No CAS ]

Reference： [1]Organic Letters,2015,vol. 17,p. 1774 - 1777

105
[ 175278-17-8 ]
2-phenyl-9-(trifluoromethoxy)-4,5-dihydro[1,4]oxazepino[4,5-a]indole [ No CAS ]
C₁₉H₁₄F₃NO₂ [ No CAS ]

Reference： [1]Organic Letters,2015,vol. 17,p. 1774 - 1777

106
[ 175278-17-8 ]
[ 540-51-2 ]
2-[2-bromo-4-(trifluoromethoxy)phenyl]amino}ethan-1-ol [ No CAS ]

Reference： [1]Organic Letters,2015,vol. 17,p. 1774 - 1777

107
[ 102-54-5 ]
[ 175278-17-8 ]
1-bromo-2-ferrocenyl-5-(trifluoromethoxy)benzene [ No CAS ]

Reference： [1]Chemical Communications,2015,vol. 51,p. 7802 - 7804

108
4-((1-carboxypentyl)oxy)-2-hydroxy-5-(thiophen-3-ylethynyl)benzoic acid [ No CAS ]
[ 175278-17-8 ]
C₂₆H₂₁BrF₃NO₆S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 2798 - 2809

109
4-((1-carboxypentyl)oxy)-2-hydroxy-5-(phenylethynyl)benzoic acid [ No CAS ]
[ 175278-17-8 ]
C₂₈H₂₃BrF₃NO₆ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 2798 - 2809

Recommend Products

Same Skeleton Products

Related Products

Isomers

Technical Information

• 1,4-Addition of an Amine to a Conjugated Enone • 1,4-Addition of an Amine to a Conjugated Enone • Acetal Formation • Acid-Catalyzed α -Halogenation of Ketones • Addition of a Hydrogen Halide to an Internal Alkyne • Alcohols from Haloalkanes by Acetate Substitution-Hydrolysis • Alcohols React with PX3 • Alkyl Halide Occurrence • Alkylation of an Alkynyl Anion • Amides Can Be Converted into Aldehydes • Amine Synthesis from Nitriles • Amine Synthesis from Nitriles • Amines Convert Acyl Chlorides into Amides • Amines Convert Esters into Amides • An Alkane are Prepared from an Haloalkane • Azide Reduction by LiAlH4 • Azide Reduction by LiAlH4 • Basicity of Amines • Benzylic Oxidation • Birch Reduction • Birch Reduction of Benzene • Blanc Chloromethylation • Buchwald-Hartwig C-N Bond and C-O Bond Formation Reactions • Chan-Lam Coupling Reaction • Chichibabin Reaction • Complete Benzylic Oxidations of Alkyl Chains • Complete Benzylic Oxidations of Alkyl Chains • Conversion of Amino with Nitro • Convert Haloalkanes into Alcohols by SN2 • Deprotonation of Methylbenzene • Diazotization Reaction • DIBAL Attack Nitriles to Give Ketones • Directing Electron-Donating Effects of Alkyl • Electrophilic Chloromethylation of Polystyrene • Enamine Formation • Esters Are Reduced by LiAlH4 to Give Alcohols • Esters Hydrolyze to Carboxylic Acids and Alcohols • Ether Synthesis by Oxymercuration-Demercuration • Ethers Synthesis from Alcohols with Strong Acids • Formation of an Amide from an Amine and a Carboxylic Acid • Formation of an Amide from an Amine and a Carboxylic Acid • Friedel-Crafts Alkylation of Benzene with Acyl Chlorides • Friedel-Crafts Alkylation of Benzene with Carboxylic Anhydrides • Friedel-Crafts Alkylation of Benzene with Haloalkanes • Friedel-Crafts Alkylation Using Alkenes • Friedel-Crafts Alkylations of Benzene Using Alkenes • Friedel-Crafts Alkylations Using Alcohols • Friedel-Crafts Reaction • General Reactivity • Grignard Reaction • Grignard Reagents Transform Esters into Alcohols • Groups that Withdraw Electrons Inductively Are Deactivating and Meta Directing • Halogenation of Alkenes • Halogenation of Benzene • Hemiaminal Formation from Amines and Aldehydes or Ketones • Hemiaminal Formation from Amines and Aldehydes or Ketones • Hiyama Cross-Coupling Reaction • Hofmann Elimination • Hofmann Rearrangement • Hydride Reductions • Hydrogenation to Cyclohexane • Hydrogenolysis of Benzyl Ether • Hydrolysis of Imines to Aldehydes and Ketones • Imine Formation from Amines and Aldehydes or Ketones • Kinetics of Alkyl Halides • Kumada Cross-Coupling Reaction • Leuckart-Wallach Reaction • Mannich Reaction • Methylation of Ammonia • Methylation of Ammonia • Nitration of Benzene • Nitrosation of Amines • Nomenclature of Ethers • Nucleophilic Aromatic Substitution • Nucleophilic Aromatic Substitution with Amine • Oxidation of Alkyl-substituted Benzenes Gives Aromatic Ketones • Peptide Bond Formation with DCC • Petasis Reaction • Preparation of Alkylbenzene • Preparation of Amines • Preparation of Ethers • Preparation of LDA • Primary Ether Cleavage with Strong Nucleophilic Acids • Reactions of Alkyl Halides with Reducing Metals • Reactions of Amines • Reactions of Benzene and Substituted Benzenes • Reactions of Dihalides • Reactions of Ethers • Reduction of an Amide to an Amine • Reduction of an Amide to an Amine • Reductive Amination • Reductive Amination • Reductive Removal of a Diazonium Group • Reverse Sulfonation——Hydrolysis • Ring Opening of Azacyclopropanes • Ring Opening of Azacyclopropanes • Ring Opening of Oxacyclobutanes • Ring Opening of Oxacyclopropane • Specialized Acylation Reagents-Vilsmeier Reagent • Stille Coupling • Strecker Synthesis • Substitution and Elimination Reactions of Alkyl Halides • Sulfonation of Benzene • Suzuki Coupling • Synthesis of 2-Amino Nitriles • Synthesis of Alcohols from Tertiary Ethers • The Acylium Ion Attack Benzene to Form Phenyl Ketones • The Claisen Rearrangement • The Nitro Group Conver to the Amino Function • The Nucleophilic Opening of Oxacyclopropanes • Ugi Reaction • Vilsmeier-Haack Reaction • Williamson Ether Syntheses

Historical Records

Related Functional Groups of
[ 175278-17-8 ]

Fluorinated Building Blocks

[ 88149-49-9 ]

2,6-Dibromo-4-(trifluoromethoxy)aniline

Similarity: 0.93

[ 886762-08-9 ]

5-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.92

[ 175278-09-8 ]

4-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.90

[ 461-82-5 ]

4-(Trifluoromethoxy)aniline

Similarity: 0.80

[ 1535-73-5 ]

3-Trifluoromethoxyaniline

Similarity: 0.79

Aryls

[ 88149-49-9 ]

2,6-Dibromo-4-(trifluoromethoxy)aniline

Similarity: 0.93

[ 886762-08-9 ]

5-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.92

[ 175278-09-8 ]

4-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.90

[ 59557-92-5 ]

2-Bromo-5-methoxyaniline

Similarity: 0.84

[ 461-82-5 ]

4-(Trifluoromethoxy)aniline

Similarity: 0.80

Bromides

[ 88149-49-9 ]

2,6-Dibromo-4-(trifluoromethoxy)aniline

Similarity: 0.93

[ 886762-08-9 ]

5-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.92

[ 175278-09-8 ]

4-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.90

[ 59557-92-5 ]

2-Bromo-5-methoxyaniline

Similarity: 0.84

[ 95970-05-1 ]

2,6-Dibromo-4-methoxyaniline

Similarity: 0.80

Ethers

[ 88149-49-9 ]

2,6-Dibromo-4-(trifluoromethoxy)aniline

Similarity: 0.93

[ 886762-08-9 ]

5-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.92

[ 175278-09-8 ]

4-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.90

[ 59557-92-5 ]

2-Bromo-5-methoxyaniline

Similarity: 0.84

[ 461-82-5 ]

4-(Trifluoromethoxy)aniline

Similarity: 0.80

Amines

[ 88149-49-9 ]

2,6-Dibromo-4-(trifluoromethoxy)aniline

Similarity: 0.93

[ 886762-08-9 ]

5-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.92

[ 175278-09-8 ]

4-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.90

[ 59557-92-5 ]

2-Bromo-5-methoxyaniline

Similarity: 0.84

[ 461-82-5 ]

4-(Trifluoromethoxy)aniline

Similarity: 0.80

Trifluoromethyls

[ 88149-49-9 ]

2,6-Dibromo-4-(trifluoromethoxy)aniline

Similarity: 0.93

[ 886762-08-9 ]

5-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.92

[ 175278-09-8 ]

4-Bromo-2-(trifluoromethoxy)aniline

Similarity: 0.90

[ 461-82-5 ]

4-(Trifluoromethoxy)aniline

Similarity: 0.80

[ 1535-73-5 ]

3-Trifluoromethoxyaniline

Similarity: 0.79

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Ghs Hazard Statements

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

; ;